arrow
C

Crystal L. Mackall

Parker Institute for Cancer Immunotherapy
H指数:71
被引数:2.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Dynamics of BCMA expression in patients with relapsed/refractory multiple myeloma receiving BCMA-directed CAR-T therapy

复发/难治性多发性骨髓瘤患者接受BCMA靶向CAR-T治疗后BCMA表达动力学

2026-04-040
OA
Long-term Follow-up of Gastrointestinal CAR T-cell Lymphoma: Homing, Clonal Expansion, and Response to Cyclosporine

胃肠道CAR T细胞淋巴瘤的长期随访:归巢、克隆性增殖及对环孢素的治疗反应

Blood
IF23.1
2025-11-270
PRE
Cover Image

封面图片

2025-11-200
OAAI
HUMANIZED ANTI-CAR ANTIBODIES AFFECT DURABLE RESPONSE TO GD2-CAR T-CELLS IN DIFFUSE MIDLINE GLIOMA

人源化抗CAR抗体影响弥漫性中线胶质瘤中GD2-CAR T细胞的持久应答

2025-11-010
OAAI
Liberalizing Hospital Proximity Requirements for Children/Young Adults with Low Burden B-ALL Receiving Tisagenlecleucel

放宽接受Tisagenlecleucel治疗的低负担B-ALL儿童/青年患者的医院邻近要求

2025-10-030
OAAI
Characterization and prediction of hematotoxicity in pediatric patients receiving tisagenlecuecel

儿科患者接受tisagenlecuecel治疗时血液毒性的表征与预测

2025-07-230
OAAI
CSF1R+ myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma

CSF1R⁺髓系-单核细胞驱动侵袭性B细胞淋巴瘤中CAR-T细胞的耐药性

2025-06-120
OAAI
Tumor-Associated Microglia Secrete Extracellular ATP to Support Glioblastoma Progression

肿瘤相关小胶质细胞分泌细胞外ATP支持胶质母细胞瘤进展

2024-12-020
PRE
MYELOID POPULATIONS MODULATE GD2 CAR T CELL ACTIVITY IN DIFFUSE MIDLINE GLIOMA
2024-11-110
PRE
Role of B Cell Recovery in Relapse Risk and CD19 Phenotype Following Real-World Use of Tisagenlecleucel for Pediatric B-Acute Lymphoblastic Leukemia: A Multi-Institutional Retrospective Study

B细胞恢复在复发风险和CD19表型中的作用:tisagenlecleucel用于儿童B淋巴细胞急性白血病真实世界应用的多机构回顾性研究

BLOOD
IF23.1
2024-11-050
PRE
The cytokine Meteorin-like inhibits anti-tumor CD8+T cell responses by disrupting mitochondrial function

细胞因子类镍纹蛋白通过破坏线粒体功能抑制抗肿瘤CD8 T细胞反应

IMMUNITY
IF26.3
2024-08-011
PRE
CAR19 monitoring by peripheral blood immunophenotyping reveals histology-speci fi c expansion and toxicity
2024-06-258
OAAI
TUMOR INFLAMMATION-ASSOCIATED NEUROTOXICITY (TIAN): A TOXICITY SYNDROME IN PATIENTS TREATED WITH IMMUNOTHERAPY FOR CENTRAL NERVOUS SYSTEM TUMORS

肿瘤炎症相关神经毒性 (TIAN): 中枢神经系统肿瘤免疫治疗患者的毒性综合征

2024-06-180
OAAI
SEQUENTIAL INTRAVENOUS AND INTRACEREBROVENTRICULAR GD2-CAR T-CELL THERAPY FOR H3K27M-MUTATED DIFFUSE MIDLINE GLIOMAS
2024-06-180
OAAI
Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma (vol 5, 101586, 2024)
2024-05-010
OAAI